Platelet reactivity and thrombogenicity in postmenopausal women

Menopause

Volumn 20, Issue 1, 2013, Pages 57-63

  Singla, Anand ^a   Bliden, Kevin P ^a   Jeong, Young Hoon ^a   Abadilla, Katrina ^a   Antonino, Mark J ^a   Muse, William C ^a   Mathew, Denny P ^a   Bailon, Oscar ^a   Tantry, Udaya S ^a   Gurbel, Paul A ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

Coronary artery disease; Menopause; Platelet reactivity; Thrombogenicity

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; ESTRADIOL; FIBRINOGEN; FOLLITROPIN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN;

ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD CLOT STRENGTH; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TIME; CHOLESTEROL BLOOD LEVEL; ESTRADIOL BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; FOLLITROPIN BLOOD LEVEL; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; METABOLIC PARAMETERS; NORMAL HUMAN; PLATELET REACTIVITY; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; THROMBOELASTOGRAPHY; THROMBOGENICITY;

ADULT; AGED; BLOOD PLATELETS; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, LDL; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INTEGRIN BETA3; MIDDLE AGED; P-SELECTIN; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEIN IIB; POSTMENOPAUSE; RISK FACTORS; THROMBOSIS;

EID: 84872075522     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31825ebafd     Document Type: Article

References (44)

1. Lanza GA. Ethnic variations in acute coronary syndromes. Heart 2004; 90:595-597.
2. Barrett-Connor E. Clinical review 162: cardiovascular endocrinology, 3: an epidemiologist looks at hormones and heart disease in women. J Clin Endocrinol Metab 2003;88:4031-4042.
3. Lerner DJ, Kannel WB. Patterns of coronary heart diseases morbidity and mortality in the sexes: a 26-year follow up of the Framingham population. Am Heart J 1986;111:383-390.
4. Schreiner PJ, Niemelä M, Miettinen H, et al. Gender differences in recurrent coronary events; the FINMONICA MI register. Eur Heart J 2001;22:762-768.
5. Isles CG, Hole DJ, Hawthorne VM, Lever AF. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet 1992;339:702-706.
6. Miller VT, LaRosa J, Barnabei V. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
7. Sarrel PM. The differential effects of oestrogens and progestins on vascular tone. Hum Reprod Update 1999;5:205-209.
8. Persky AM, Green PS, Stubley L, et al. Protective effect of estrogens against oxidative damage to heart and skeletal muscle in vivo and in vitro. Proc Soc Exp Biol Med 2000;223:59-66.
9. Subbiah MT. Estrogen replacement therapy and cardioprotection: mechanisms and controversies. Braz J Med Biol Res 2002;35:271-276.
10. Subbiah MTR. Mechanisms of cardioprotection by estrogens. Proc Soc Exp Biol Med 1998;217:23-29.
11. Perlman J, Wolf P, Finucane F, Madans J. Menopause and the epidemiology of cardiovascular disease in women. Prog Clin Biol Res 1989; 320:283-312.
12. Wuest JH Jr, Dry TJ, Edwards JE. The degree of coronary atherosclerosis in bilaterally oophorectomized women. Circulation 1953;7:801-809.
13. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-762.
14. SchrottHG, Bittner V, Vittinghoff E, Herrington DM, Hulley S. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. JAMA 1997;277: 1281-1286.
15. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820.
16. Gurbel PA. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. Rev Cardiovasc Med 2006;7(Suppl 4):S20-S28.
17. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975;253:355-357.
18. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost 1997;77:748-756.
19. Suzuki S, Matsuno K, Kondoh M. Primary hemostasis during women's life cycle measured by Thrombostat 4000. Semin Thromb Hemost 1995;21(Suppl 2):103-105.
20. Tarantino MD, Kunicki TJ, Nugnet DJ. The estrogens receptor is present in human megakaryocytes. Ann N Y Acad Sci 1994;714:293-296.
21. Khetawat G, Faraday N, Nealen ML, et al. Human megakaryocytes and platelets contain the estrogen receptor A and androgen receptor (AR): testosterone regulates AR expression. Blood 2000;95: 2289-2296.
22. Leng XH, Zhang W, Nieswandt B, Bray PF. Effects of estrogen replacement therapies on mouse platelet function and glycoprotein VI levels. Circ Res 2005;97:415-417.
23. Aldrighi JM, Oliveira RL, D'Amico E, et al. Platelet activation status decreases after menopause. Gynecol Endocrinol 2005;20:249-257.
24. Gu J, Yang D, Wang L, Yin S, Kuang J. Effects of hormone replacement therapy on platelet activation in postmenopausal women. Chin Med J 2003;116:1134-1136.
25. Roshan TM, Normah J, Rehman A, Naing L. Effect of menopause on platelet activation markers determined by flow cytometry. Am J Hematol 2005;80:257-261.
26. Gurbel PA, Bliden KP, Cohen E, et al. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Blood Coagul Fibrinolysis 2008;19:268-275.
27. Cho EJ, Min YJ, Oh MS, et al. Effects of the transition from premenopause to postmenopause on lipids and lipoproteins: quantification and related parameters. Korean J Intern Med 2011;26:47-53.
28. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83-90.
29. Torng PL, Su TC, Sung FC, et al. Effects of menopause on intraindividual changes in serum lipids, blood pressure, and body weight: the Chin-Shan Community Cardiovascular Cohort study. Atherosclerosis 2002;161: 409-415.
30. Graff-Iversen S, Thelle DS, Hammar N. Serum lipids, blood pressure and body weight around the age of the menopause. Eur J Cardiovasc Prev Rehabil 2008;15:83-88.
31. Gurbel PA, Bliden KP, Saucedo JF et al. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. J Am Coll Cardiol 2009;53: 648-657.
32. Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1990;74:77-81.
33. Dolan G, Neal K, Cooper P, Brown P, Preston FE. Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 1994;86:798-803.
34. Sagripanti A, Carpi A. Natural anticoagulants, aging, and thromboembolism. Exp Gerontol 1998;33:891-896.
35. Caparevi( Z, Kosti( N. The influence of age and the beginning of menopause on the lipid status, LDL oxidation, and CRP in healthy women. Srp Arh Celok Lek 2007;135:280-285.
36. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
37. Park CS, Ihm SH, Yoo KD, et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. Am J Cardiol 2010;105: 1284-1288.
38. Kurtz EG, Ridker PM, Rose LM, et al. Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes. Menopause 2011;18:23-29.
39. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Circulation. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-733.
40. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304.
41. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-313.
42. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, et al. Evidencebased guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007;115:1481-1501.
43. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
44. Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med 2011;124:199-205.